Biotalys Secures Key Patents for Sustainable Crop Solutions
Biotalys Enhances Its Intellectual Property with New Patents
Biotalys, an Agricultural Technology company focused on sustainable crop protection, has made a significant advancement by securing patents for its innovative biofungicide, EVOCA. This development was recognized by both the European Patent Office and the United States Patent and Trademark Office, marking a key milestone for the company.
CEO's Perspective on Patent Achievements
Kevin Helash, the Chief Executive Officer, expressed satisfaction regarding the patent grants, appreciating the extensive examination that led to this substantial recognition. Helash stated, “These decisions affirm the innovative elements of our protein-based biocontrol candidate, EVOCA. They offer Biotalys the necessary exclusivity for collaborating with commercial partners, enabling them to produce and distribute EVOCA effectively in Western markets.”
Focus on Global Expansion of Patent Protection
Biotalys is not limiting its patent ambitions to just Europe and the U.S. The company is actively pursuing patent protection for EVOCA’s active ingredient in several countries, including Argentina, Brazil, and South Africa. These regions present significant opportunities within the agricultural sector. By building a robust portfolio across various jurisdictions, Biotalys is positioning itself strategically within the crop protection landscape.
Understanding EVOCA's Unique Contributions
EVOCA stands out as a novel protein-based biofungicide that introduces a new resistance classification, showcasing its efficacy in managing fungal diseases affecting fruits and vegetables. The product has recorded strong performance in trials, demonstrating effectiveness under varied conditions. Specifically, EVOCA is under regulatory review by the U.S. Environmental Protection Agency and the Dutch College voor Toelating van Gewasbeschermingsmiddelen en Biociden, aiming for swift market entry.
Future Prospects with EVOCA NG
The success of EVOCA is paving the way for another promising product, EVOCA NG, expected to be Biotalys’ first fungicide derived from its AGROBODY technology platform. Both EVOCA and EVOCA NG contain the same active ingredient, which is now safeguarded by the patents recently granted.
Company Overview
Founded in 2013, Biotalys emerged as a spin-off from the VIB (Flanders Institute for Biotechnology) and has been listed on Euronext Brussels since July 2021. The company specializes in developing protein-based biocontrol solutions aimed at replacing traditional chemical pesticides. With a commitment to enhancing food safety and sustainability, Biotalys continues to explore innovative approaches in agriculture.
Contact Information for Biotalys
For further information regarding Biotalys and its products, please reach out to:
Toon Musschoot, Head of Investor Relations and Communications
T: +32 (0)9 274 54 00
E: IR@biotalys.com
Frequently Asked Questions
What is EVOCA?
EVOCA is an innovative protein-based biofungicide developed by Biotalys to combat fungal diseases in crops, particularly fruits and vegetables.
Which markets have approved the EVOCA patents?
The patents for EVOCA have been granted in both Europe and the United States, enhancing its market access.
What future products are planned following EVOCA?
Biotalys plans to launch EVOCA NG, which shares the same active ingredient as EVOCA and is derived from its AGROBODY technology platform.
How does Biotalys contribute to sustainability in agriculture?
By developing alternatives to conventional chemical pesticides, Biotalys aims to create safer and more sustainable agricultural practices with its biocontrol solutions.
Where can I find more information about Biotalys?
Additional information about Biotalys and its activities can be found on the company's official website.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.